Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.34 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12513050 | 0.93 | NPC1 (0.39) | RAB9ANPC1GPR119HRH3MEN1 | |
| SCHEMBL2372270 | 0.92 | GPR119 (0.37) | RAB9ANPC1GPR119HRH3DRD2 | |
| SCHEMBL2371088 | 0.91 | HRH3 (0.37) | RAB9ANPC1GPR119HRH3KCNH2 | |
| SCHEMBL2372154 | 0.91 | GPR119 (0.36) | RAB9ANPC1GPR119HRH3KCNH2 | |
| SCHEMBL1839336 | 0.89 | RAB9A (0.38) | RAB9ANPC1GPR119MEN1KMT2A | |
| SCHEMBL1841959 | 0.88 | RAB9A (0.41) | RAB9ANPC1GPR119HRH3MEN1 | |
| SCHEMBL2370849 | 0.88 | GPR119 (0.48) | RAB9ANPC1GPR119HRH3KCNH2 | |
| SCHEMBL2220450 | 0.88 | GPR119 (0.37) | RAB9ANPC1GPR119HRH3DRD2 | |
| SCHEMBL1842890 | 0.87 | NPC1 (0.41) | RAB9ANPC1GPR119 | |
| SCHEMBL2216789 | 0.87 | GPR119 (0.41) | RAB9ANPC1GPR119HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178054-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110178054-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| EP-2321305-A1 | HETEROCYCLIC GPCR AGONISTS | Prosidion Limited (GB) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010004348-A1 | HETEROCYCLIC GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010004348-A1 | HETEROCYCLIC GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178054-A1 | Heterocyclic GPCR Agonists | GPR119, GCGR, GPR27 | RAB9A 585/4885NPC1 817/4885GPR119 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.